| Journal | Neurogastroenterology and motility |
| Study Type | Cohort |
| Population | Human participants |
This item covers developments relevant to cannabis medicine and clinical practice. Clinicians monitoring evidence in this area should review the source material.
Cyclical Vomiting Syndrome (CVS) poses a significant financial burden on the healthcare system due to frequent emergency department (ED) visits and hospitalizations. Data on the impact of cannabis use in CVS is conflicting. This study evaluates the impact of cannabis use on outcomes in individuals with CVS using real-world data. A retrospective cohort study was conducted using the TriNetX research network to identify adults (≥ 18 years) with CVS. Patients were categorized into two groups: CVS with cannabis use and CVS without cannabis use (controls). Using propensity score matching on demographics, body mass index, comorbidities and treatments (e.g., abortive and prophylactic therapy) cohorts were matched 1:1. Outcomes included all-cause ED visits and hospitalizations. A total of 18,588 individuals with CVS and cannabis use were matched with 18,588 individuals with CVS who did not use cannabis (controls). Cannabis users were younger (mean age [SD]: 31.9 [12.5] vs. 39.0 [19.9] years) an
“This is a development worth tracking. The clinical implications will become clearer as more evidence accumulates.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
This study item was assembled from normalized source metadata and pipeline scoring.
